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BY-NC-ND license (http://creativecomBackground/Purpose: Escherichia coli is a common pathogen to cause clinical and subclinical
mastitis in cows. A total of 57 E. coli isolates from raw milk from cows were characterized
genetically and biochemically.
Methods: Extended-spectrum b-lactamase (ESBL) genes, the mechanism for fluoroquinolone
resistance, and variations in virulence genes and genomes of these E. coli isolates were inves-
tigated by the antimicrobial susceptibility test, simplex and multiplex polymerase chain reac-
tion (PCR), and pulsed-field gel electrophoresis (PFGE).
Results: All E. coli isolates were resistant to cloxacillin (100%) and to a lesser extent (50%) to
tetracycline, neomycin, gentamycin, ampicillin, ceftriaxone, cefotaxime (CTX), and ceftazi-
dime (CAZ). Nearly 70% of the isolates were resistant to at least two antimicrobials and
28.1% carried AmpA and AmpC genes simultaneously. The predominant bla gene was blaTEM,
followed by blaCMY, blaCTX, blaSHV, and blaDHA. Among the six (10.5%) ESBL-producing E. coli
carrying blaCTX-M15, blaCTX-M55, or blaCTX-M14, two isolates 31 of ST410 in the ST23 complex
and 58 of ST167 in the ST10 complex were also resistant to ciprofloxacin, enrofloxacin,
and levofloxacin, with mutations at codon 83 from serine to leucine and codon 87 from as-
partic acid to asparagine in GyrA and at codon 80 from serine to isoleucine in ParC. These
isolates were genetically diverse in pulsotype analysis, lacked toxin genes of humanof Microbiology, Immunology, and Biopharmaceutics, National Chiayi University, 300 University Road,
edu.tw (C. Chu).
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Fluoroquinolone-resistant ESBL-E. coli from cow 893pathogenic E. coli and carried mostly the prevalent virulence genes fimH, papGII, and
a-hemolysin.
Conclusion: Lacking virulence genes examined, genetic diverse E. coli isolates are unrelated
to human pathogenic E. coli. Enhancing sanitation in milk processing and transportation is
needed to eliminate multidrug-resistant (MDR), fluoroquinolone-resistant, and ESBL-
producing E. coli isolates.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Mastitis in cows and goats affects milk quality, human
safety, and the income of the farming industry worldwide.
Cases of subclinical mastitis are much higher than those of
clinical mastitis. The predominant pathogens causing
mastitis are Gram-negative bacteria (25e30%), coagulase-
negative Staphylococcus (20%), Staphylococcus aureus and
Escherichia coli (5e10% each), Streptococcus and
Enterococcus (2e5%), and other species (< 2%).1e5 In
Taiwan, the predominant pathogens causing mastitis in
dairy cows are E. coli (16.8%), Staphylococcus spp.
(23.3%), Streptococcus spp. (14.5%), Enterococcus spp.
(20.1%), and other Gram-negative versus Gram-positive
(19.2% vs. 3.8%) pathogens.6 As normal intestinal flora of
the intestine, E. coli produces vitamins B and K and in-
hibits the growth of pathogens in the intestine,7 and be-
comes diverse genetic groups and opportunistic pathogens
to humans by incorporating different pathogenicity islands
with virulence genes, for example, enterotoxigenic E. coli
(ETEC) with genes for heat-stable toxin and heat-labile
toxin,8 enterohemorrhagic E. coli (EHEC) with genes for
Shiga-like toxin I and II,9 and enteropathogenic E. coli
(EPEC) with genes for bundle-forming pilus.10 The emer-
gence of multidrug-resistant (MDR) bacteria and the
transmission of these bacteria from foods to humans have
become serious public health problems in treating their
infection.11,12
b-lactamase can hydrolyze the b-lactam rings of
expanded-spectrum cephalosporins (except cephamycins
and carbapenems) and monobactams and then inactivates
these compounds. Application of third-generation cepha-
losporins increases extended-spectrum b-lactamase
(ESBL) Enterobacteriaceae, which are relatively high in
food animals and reveal a high genetic diversity,13,14
indicating that farm animals are a reservoir of ESBL-
producing bacteria which can infect humans. Recently,
ESBL-producing E. coli has been observed in economically
important animals in Europe15,16 and Asia,17 in meat, fish,
and raw milk,18,19 and in healthy dairy cattle and retail
meat in the USA.20,21 Furthermore, fluoroquinolone- and
carbapenem-resistant E. coli isolates have been reported
in humans. Here, we investigated antimicrobial suscepti-
bility, ESBL-producing genes, mutations in GyrA and ParC
for fluoroquinolone resistance, and differences in viru-
lence genes and genomes for mastitis-associated E. coli
isolates.Methods
Mastitis-associated bacterial species
A total of 412 milk samples from cows with clinical or
subclinical mastitis were collected from 13 farms in Yun-
lin, Chiayi, and Tainan in Southern Taiwan based on the
California mastitis test of microcolloid formation22 and
these samples were directly plated on Eosin Methylene
Blue (EMB) agar to screen for E. coli. Bacterial colonies
were further identified as E. coli by API 20E and poly-
merase chain reaction (PCR) amplification of the E. coli-
specific gene mdhR. Hemolysin types of each isolate were
determined by blood agar. Informed consent was obtained
from all farm owners prior to the start of this study. The
use of all bacteria was supervised by the Biological Secu-
rity Committee of the National Chiayi University, Chiayi,
Taiwan in accordance with the laws of Taiwan. The milk
samples were collected by county governors based on the
guidelines of Animal Use Protocol, the Institutional Animal
Care and Use Committee, National Chiayi University.
Antimicrobial susceptibility test
Antimicrobial susceptibility to ampicillin, cefepime,
cefotaxime (CTX), ceftazidime (CAZ), ceftriaxone, cipro-
floxacin, cloxacillin, enrofloxacin, ertapenem, genta-
micin, levofloxacin, meropenem, neomycin, and
tetracycline was determined by the disc diffusion method
and the Clinical and Laboratory Standards Institute stan-
dard.23 ESBL isolates were confirmed by determining their
resistance to CAZ, CTX, CAZ/clavulanic acid, and CTX/
clavulanic acid. E. coli ATCC 25922 was used as the
reference strain.
PCR detection of genes for b-lactamase, virulence
factors, and pathogenic E. coli
The primers used to amplify five b-lactamase genes, 12
virulence genes of uropathogenic E. coli, and 10 toxin
genes of other pathogenic E. coli are listed in
Table 1.24e29 Three multiplex PCR sets were developed.
Multiplex PCR I was used to detect genes blaSHV, blaCTX-M3,
blaCTX-M14, blaTEM, and blaDHA. Twelve virulence genes
were amplified by multiplex PCR II for hlyA, usp, sat,
fyuA, ironN, iutA, and iucD and multiplex PCR III for fimH,
Table 1 Primer sequences and PCR product sizes of genes for antimicrobial resistance and virulence factors
PCR Set Gene Primer Nucleotide sequence（50 / 30） PCR product size (bp)
Multiplex Ia Class A b-lactamase
blaCTX-M3 F
R
AATCA CTGCG CCAGT TCACG CT
GAACG TTTCG TCTCC CAGCT GT
479
blaCTX-M14 F
R
TACCG CAGAT AATAC GCAGG TG
CAGCG TAGGT TCAGT GCGAT CC
355
blaSHV F
R
AACGG AACTG AATGA GGCGC T
TCCAC CATCC ACTGC AGCAG CT
141
blaTEM F
R
GAAGA TCAGT TGGGT GCACG AGT
CAACT TTATC CGCCT CCATC CAGT
520
Class C b-lactamase
blaDHA F
R
AACTT TCACA GGTGT GCTGG GT
CGTAC GCATA CTGGC TTTGC
405
Simplex blaCMY-2 F
R
CTGAC AGCCT CTTTC TCCAC A
CTACG TAGCT GCCAA ATCCA C
1100
Multiplex II hlyA F
R
AACAA CGATA AGCAC TGTTC TGG
CCATA TAAGC GGTCA TTCCC G
1177
fyuA F
R
GGCTT TATCC TCTGG CCTT
GAAAA CCCAG TCATC GGTGG
878
iroN F
R
CTCTG GTGGT GGAAG CC
TGTCG GTACA GGCGG TTC
815
usp F
R
GGAAA ATGGT CGCTC AGTGG
CTGTA GTGAA TCTCA TCGTG TAGTC
992
sat F
R
TCAGA AGCTC AGCGA ATCAT TG
CATTA TCACC AGTAA AACGC ACC
931
iutA F
R
CACTC CGGTA CTCCA GTCA
CCTCC AACCA GATGT TCTTC G
688
iucD F
R
CCGGA GAAGC CTGAA ATATA TTCA
CCGGA TTGTC ATATG CAGAC C
584
Multiplex III fimH F
R
GTTTA TAATT CGAGA ACGGA TAAGC C
GTGCA TAATT TGCCG TTAAT CCC
494
cnf1 F
R
TTCTT CTGTA CTTCC CCCAG
TGAGC GGCAT CTACT ATGAA GT
407
kpsMTII F
R
CATCA GACGA TAAGC ATGAG CA
TGCGC ATTTG CTGAT ACTGT
270
papGII F
R
GGGCC CCCAA GTAAC TC
GGATG AGCGG GCCTT TG
188
traT F
R
CATAA CCACG GTTCA GCCAT C
TTGCA CTGGT CAGTT CCAC
328
Specific PCR sets for EHECb stx1 F
R
CAGTT AATGT GGTGG CGAAG G
CACCA GACAA TGTAA CCGCT G
348
stx2 F
R
ATCCT ATTCC CGGGA GTTTA CG
GCGTC ATCGT ATACA CAGGA GC
584
Specific PCR sets for EPECc eae F
R
TCAAT GCAGT TCCGT TATCA GTT
GTAAA GTCCG TTACC CCAAC CTG
482
bfp F
R
GGAAG TCAAA TTCAT GGGGG TAT
GGAAT CAGAC GCAGA CTGGT AGT
300
Specific PCR sets for ETECc Lt F
R
GCACA CGGAG CTCCT CAGTC
TCCTT CATCC TTTCA ATGGC TTT
218
stII F
R
AAAGG AGAGC TTCGT CACAT TTT
AATGT CCGTC TTGCG TTAGG AC
129
Specific PCR sets for EIECd virF F
R
AGCTC AGGCA ATGAA ACTTT GAC
TGGGC TTGAT ATTCC GATAA GTC
618
ipaH F
R
CTCGG CACGT TTTAA TAGTC TGG
GTGGA GAGCT GAAGT TTCTC TGC
933
Specific PCR set for DAECd daaE F
R
GAACG TTGGT TAATG TGGGG TAA
TATTC ACCGG TCGGT TATCA GT
542
Specific PCR set for EAggEC3d aafII F
R
CACAG GCAAC TGAAA TAAGT CTGG
ATTCC CATGA TGTCA AGCAC TTC
378
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Table 1 (continued )
PCR Set Gene Primer Nucleotide sequence（50 / 30） PCR product size (bp)
Quinolone-resistant
determining region
gyrAe F
R
GCGCGGGCTGTGTTATAATT
CCGTGCCGTCATAGTTATCAA
519
parCf F
R
AAACCTGTTCAGCGCCGCATT
GTGGTGCCGTTAAGCAAA
391
a The PCR method was described by Chia et al24 and primers for blaDHA was designed in this study.
b The PCR method was described by Cebula et al.25
c The PCR method was described by Stacy-Phipps et al.26
d The method was described by Vidal et al.27
e The method was described by Cattoir et al.28
f The method was described by Wada et al.29
DAECZ diffuse adherent Escherichia coli; EAggEC3Z enteroaggregative Escherichia coli; EHECZ enterohemorrhagic Escherichia coli;
EIEC Z enteroinvasive Escherichia coli; EPEC Z enteropathogenic Escherichia coli; ETEC Z enterotoxigenic Escherichia coli.
Fluoroquinolone-resistant ESBL-E. coli from cow 895cnf1, traT, kpsMTII, and papGII. blaCMY-2 was identified by
single PCR. A 50-mL PCR reagent included 5 mL of DNA
template, 0.2 mM of each primer, 5 mL of 10X PCR reaction
buffer, 200 mM of deoxyribonucleoside triphosphates
(dNTPs), and 1.4 U Taq DNA polymerase. The PCR condi-
tions were as follows: predenaturation at 95C for 5 mi-
nutes, 30 cycles of denaturation at 95C for 1 minute,
annealing at 60C for 1 minute and extension at 72C for 1
minute, and a final extension at 72C for 10 minutes. Toxin
genes for pathogenic E. coli were amplified with previ-
ously described PCR conditions.24e29 All PCR products
were separated on 2% agarose gels at 50 V for 120 mi-
nutes. After ethidium bromide staining and UV illumina-
tion, gel images were recorded and analyzed.Sequence analysis of quinolone-resistance
determining regions of gyrA, parC, and blaCTX-M
The quinolone-resistance determining regions of gyrA and
parC genes were amplified from two fluoroquinolone
resistant strains and sensitive strains with the PCR primers
listed in Table 1. PCR products were purified and
sequenced. The blaCTX-M was amplified with the primer set
in Table 1 and sequenced. The sequences were compared
to the NCBI database by the Blast program.Pulsed-field gel electrophoresis analysis
The PulseNet standardized laboratory pulsed-field gel
electrophoresis (PFGE) protocol for molecular subtyping of
E. coli O157:H7, non-typhoidal Salmonella serotypes, and
Shigella sonnei was used to analyze the isolates.30 A total of
10 U of XbaI was used for restriction digestion. Digested
DNA fragments were separated by the CHEF-DRIII system
(BioRad, Hercules, CA, USA) in 1% agarose gel with 0.5X TBE
running buffer at 14C in conditions of 6 V/cm, 120 sepa-
ration angle, and switching time of 4w70 seconds for 18
hours and another run for 4 hours in the same condition,
with only change of voltages to 4 V/cm. PFGE images were
analyzed and a unique PFGE pattern was defined as one or
two DNA bands differing between PFGE patterns of two
isolates.Results
Antimicrobial susceptibility of E. coli
E. coli from milk samples of the cows with clinical mastitis
differed in prevalence of 13.8% (57/412) in total, 51.6% in
Yunlin, 10.8% in Chiayi, and 4.1% in Tainan. Based on
resistance to 1e12 antimicrobials, the number of antibio-
grams ranged from 13 in Yunlin to six in Chiayi and Tainan;
however, the highest antimicrobial resistance was found in
two isolates from Chiayi and Tainan (Table 2). Although all
57 isolates were resistant to cloxacillin, a drug used to treat
S. aureus, a total of 33.3% of the isolates were susceptible
to the remaining 11 antimicrobials, with a prevalence of
64.7% in Chiayi, 37.5% in Tainan, and 15.6% in Yunlin.
Prevalence of the resistance to traditional antimicrobials
was 51% for tetracycline, 42% for neomycin, and 19% for
gentamicin.
Regarding resistance to beta-lactam antimicrobials, 54%
isolates were resistant to ampicillin of the penicillin group,
while < 25% isolates were resistant to CAZ, CTX, and cef-
triaxone of the third-generation cephalosporins, and one
isolate was resistant to cefepime (the 4th-generation
cephalosporin). Furthermore, only six (10.7%) ESBL-
producing isolates were identified and all revealed resis-
tance to 7e11 antimicrobials (Table 2). ESBL-producing
isolates VMEC31 and VMEC58 were also resistant to fluo-
roquinolones (ciprofloxacin, enrofloxacin, and levofloxacin)
and revealed mutations at codon 83 from serine to leucine
and codon 87 from aspartic acid to asparagine in GyrA, and
at codon 80 from serine to isoleucine in ParC. These isolates
reduced susceptibility to carbapenems.
Variations in bla genes
Among five bla genes encoding AmpA and AmpC lactamase,
the prevalent bla genes in order were blaTEM (47%), blaCMY
(40%), blaCTX [blaCTX-M3-like (9%) and blaCTX-M14-like (4%)],
blaSHV (9%), and blaDHA (2%) (Table 3). Over 70% of the
isolates contained at least one bla gene, while the number
of isolates without the bla gene was identical to those
resistant only to cloxacillin in Yunlin and Tainan, not Chiayi
(Table 3). The predominant bla genes were blaTEM in 43.9%
Table 2 Prevalence of antimicrobial resistance in different counties
Resistance
no.
Resistance (%) ESBL Yunlin Chiayi Tainan Total,
n (%)Penicillin Cephalosporin Fluoroquinolone GEN NEO TET
CLO AMP CAZ CTX CRO FEP CIP ENR LVX CTX CAZ n (%) n (%) n (%)
1 R S S S S S S S S S S S   5 (15.6) 11 (64.7) 3 (37.5) 19 (33.3)
2 R S S S S S S S S S S R   1 (3.1) 0 (0.0) 0 (0.0) 1 (1.8)
R S S S S S S S S S R S   2 (6.3) 0 (0.0) 0 (0.0) 2 (3.5)
R R S S S S S S S S S S   3 (9.4) 1 (5.9) 0 (0.0) 4 (7.0)
3 R S S S S S S S S S R R   2 (6.3) 1 (5.9) 0 (0.0) 3 (5.3)
R S S S S S S S S R R S   1 (3.1) 0 (0.0) 0 (0.0) 1 (1.8)
R R S S S S S S S S S R   6 (18.8) 1 (5.9) 0 (0.0) 7 (12.3)
R R S S S S S S S S R S   2 (6.3) 0 (0.0) 0 (0.0) 2 (3.5)
4 R R S S S S S S S S R R   0 (0.0) 2 (11.8) 0 (0.0) 2 (3.5)
R R S R S S S S S S S R   0 (0.0) 0 (0.0) 1 (12.5) 1 (1.8)
5 R R S R S S S S S S R R   3 (9.4) 0 (0.0) 1 (12.5) 4 (7.0)
R R S S S S S S S R R R   2 (6.3) 0 (0.0) 1 (12.5) 3 (5.3)
6 R R S R S S S S S R R R   0 (0.0) 0 (0.0) 1 (12.5) 1 (1.8)
R R S R R S S S S S R R   1 (3.1) 0 (0.0) 0 (0.0) 1 (1.8)
7 R R S R R S S S S R R R þ  1 (3.1) 0 (0.0) 0 (0.0) 1 (1.8)
8 R R R R R S S S S R R R þ þ 3 (9.4) 0 (0.0) 0 (0.0) 3 (5.3)
11 R R R R R S R R R R R R þ þ 0 (0.0) 0 (0.0) 1 (12.5) 1 (1.8)
R R R R R R R R R R S R þ þ 0 (0.0) 1 (5.9) 0 (0.0) 1 (1.8)
Total, n (%) 57 (100) 31 (54) 5 (9) 13 (23) 7 (12) 1 (2) 2 (4) 2 (4) 2 (4) 11 (19) 24 (42) 29 (51) 6 (11) 5 (9) 32 (100) 17 (100) 8 (100) 57 (100)
AMP Z ampicillin; CAZ Z ceftazidime; CLO Z cloxacillin; CRO Z ceftriaxone; CIP Z ciprofloxacin; CTX Z cefotaxime; ENR Z enrofloxacin; ESBL Z extended-spectrum b-lactamase;
ETP Z ertapenem; FEP Z cefepime; GEN Z gentamicin; LVX Z levofloxacin; NEO Z neomycin; TET Z tetracycline.
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Table 3 Prevalence of different beta-lactamase genes in three counties
No. of resistant
gene
AmpA bla AmpC bla ESBL County Total,
n (%)TEM SHV CTX-M-3 CTX-M-14 DHA CMY CAZ CTX Yunlin Chiayi Tainan
0         5 (15.6) 8 (47.1) 3 (37.5) 16 (28.1)
1 D        8 (25.0) 3 (17.6) 2 (25.0) 13 (22.8)
 D       1 (3.1) 2 (11.8) 0 3 (5.3)
   D     1 (3.1) 0 0 1 (1.8)
    D    1 (3.1) 0 0 1 (1.8)
     D   4 (12.5) 3 (17.6) 0 7 (12.3)
2 D     D   7 (21.9) 0 1 (12.5) 8 (14.0)
  D   D D D 0 1 (5.9) 0 1 (1.8)
   D  D  D 1 (3.1) 0 0 1 (1.8)
3 D D    D   1 (3.1) 0 1 (12.5) 2 (3.5)
D  D   D D D 3 (9.4) 0 1 (12.5) 4 (7.0)
Total, n (%) 27 (47) 5 (9) 5 (9) 2 (4) 1 (2) 23 (40) 5 (9) 6 (11) 32 17 8 57 (100)
CAZ Z ceftazidime; CMY Z ; CTX Z cefotaxime; DHA Z ; ESBL Z extended-spectrum b-lactamase; SHV Z ; TEM Z .
Fluoroquinolone-resistant ESBL-E. coli from cow 897of isolates carrying one bla gene, blaTEM and blaCMY in 17.6%
of isolates with two bla genes, and blaTEM, blaCTX-M3, and
blaCMY in 10.5% of isolates with three bla genes. The latter
two groups all contained AmpC blaCMY and at least one
AmpA bla gene. Isolates with three bla genes were only
observed in Yunlin and Tainan. In contrast to CAZESBL and
CTXESBL phenotypes of E. coli carrying blaCTX-M3-like, E. coli
with blaCTX-M14-like exhibited only a CTX
ESBL phenotype or
non-ESBL phenotype. Sequence analysis of blaCTX-M3-like
genes determined blaCTX-M55 for isolates 39, 42, 43, and 58
and blaCTX-M15 for isolate 31.
Differences in virulence genes
Examination of hemolysin types found a-hemolysin in 96.7%
(55/57) isolates and b- and g-hemolysin in one isolate,
respectively. PCR amplification of toxin genes only identi-
fied eae of EPEC in one isolate and lacked other toxin genes
of EHEC, ETEC, enteroinvasive E. coli (EIEC), diffuse
adherent E. coli (DAEC), and enteroaggregative E. coli
(EAggEC). Among the other 13 virulence genes for urinary
tract infection (UTI)-associated E. coli in humans, almost
all isolates carried fimH encoding type 1 fimbriae and
papGII encoding P fimbriae, and < 10% of isolates consisted
of the kpsMTII encoding capsule and cnf1 and hlyA encoding
cytotoxin (Table 4). Both capsule and cytotoxin genes were
only present in the isolates from Yunlin (14%, 8/57) and
Chiayi (2%, 1/57) and were absent in Tainan, while both
fimbriae and cytotoxin genes were only observed in the
isolates from Yunlin (7%, 4/57) and Tainan (2%, 1/57).
Furthermore, siderophore genes were present in < 40% of
isolates and ranged from 10.5% (6/57) for iroN, encoding
the aerobactin receptor, 40.3% (23/57) for iutA and 15.8%
for iucD, encoding salmochelin, and 17.5% for fyuA,
encoding the yersiniabactin receptor. However, almost all
isolates with iucD carried iutA.
Phylogenetic analysis
PFGE analysis separated 57 isolates into 39 pulsotypes and
nontypeable (Fig. 1 and Table 3). Clonal dissemination wasonly observed in pulsotypes 5, 16, 22, and nontypeable in
Yunlin, and in pulsotypes 20, 25, 32, and nontypeable in
Chiayi. These nontypeable isolates differed in their viru-
lence genes. Pulsotypes of two fluoroquinolone-resistant
strains were pulsotype 28 for isolate 31 and nontypeable
for isolate 58.
Discussion
E. coli are important pathogenic sources for cow mastitis
with a prevalence of 5e10% in South Eastern Ethiopia,1
15.9% for clinical mastitis in Estonia,31 and 4.8% for sub-
clinical mastitis.32 In this study, genetically diverse E. coli
isolates were the predominant pathogens from the milk of
cows with clinical mastitis (Fig. 1), suggesting that these E.
coli isolates may originate from the environment. Virulence
factors, such as S and P fimbriae and CNF1, are important
for the severity and persistence of mastitis.33 Examining
the virulence and toxin genes for disease in cattle, these E.
coli isolates carried fimH, papGII, and a-hemolysin genes
more prevalent than other virulence genes (> 80%
vs. < 40%; Fig. 1, Table 3), implying that these three genes
are important for clinical mastitis in cows and that these E.
coli isolates was not associated with EPEC, EHEC, ETEC,
EIEC, DAEC, and EAggEC pathogenic to humans.
Subtherapeutic antimicrobials are frequently used in
animal feed, leading to an increase in antimicrobial-
resistant bacteria in the animal. In feedlot cattle, given
feed with subtherapeutic antimicrobials, the isolates
increased resistance to sulfamethoxazole and chloram-
phenicol, and did not change other antimicrobial resistance
patterns.34 Recently, MDR E. coli isolates have emerged
from cows with mastitis. Antimicrobial resistance of
mastitis-associated E. coli isolates differs among countries
from low resistance in Sweden and higher resistance in
France.35 Additionally, E. coli isolates from the feedlot
cattle were less resistant to ampicillin (5.9e24.3%), kana-
mycin (l5.9%), streptomycin (5.9e15.6%), tetracycline
(5.9e13.5%), susceptible to cefotaxime, ceftiofur, chlor-
amphenicol, gentamicin, and nalidixic acid, and not ESBL
producers,32,34 while other research reported the isolates
Table 4 Prevalence of virulence genes in three counties
No.
factor
Fimbriae Capsule Cytotoxin Siderophore Pulsotype Number County Sum
fimH þ
papGII
kpsMTII cnf1 þ
hlyA
iroN iutA iucD fyuA Yunlin Chiayi Tainan
0        18;24/25/
26/31;40
1;1/2/
1/1/;1
1 5 1 7
2 e  þ     1/22 1/2 3 17
       4/7/8/11/
19/23;20/
32/33;38
1/1/1/
1/1/1;
2/3/1;1
6 6 1
 þ þ  ND 1 1
3 þ    þ   8/14/16/
17/21,29/
ND;37
1/1/2/
1/1;1/
3;1
6 4 1 19
þ      þ 3/ND;34 1/2;1 3 1
þ   þ    27;36 1;1 1 1
þ þ      10/15 1/1 2
4 þ  þ     20 1 1 3
þ    þ þ  35 1 1
5 þ þ     þ 3 1 1 8
þ þ   þ   6 1 1
þ    þ þ þ 13 1 1
þ  þ þ  þ  12 1 1
þ þ   þ þ  2/5 1/3 4
6 þ   þ þ þ þ 39 1 1 3
þ  þ þ   þ 9 1 1
þ  þ þ þ   9 1 1
7 þ þ  þ þ þ þ 28 1 1 1
Total 48 (84.2) 9 (15.8) 8 (14.0) 6 (10.5) 23 (40.3) 9 (15.8) 10 (17.5) 32 17 8 57
898 Y. Su et al.more resistant to ampicillin (100%), chloramphenicol
(75.4%), gentamycin (54%), neomycin (43.2%), streptomycin
(97.3%), sulfonamide (98.6%), and tetracycline (100%).36
However, resistance to fluoroquinolones or cephalosporins
is still uncommon among coliforms isolated from bovine
mastitis. Although < 50% isolates were resistant to ampi-
cillin, gentamycin, neomycin, and tetracycline, an ESBL
producer was identified in this study (Table 3).Figure 1. Pulsed-field gel electrophoresis analysis of clinicBeta-lactam and fluoroquinolone antimicrobials have
been frequently used to treat bacterial infections in vet-
erinary hospitals and farms. The use of a third-generation
cephalosporin, ceftiofur, in dairy cows and cattle reduces
the susceptibility to ceftriaxone in E. coli and does not
have an effect on the maintenance and dissemination of
blaCMY-2-bearing plasmid.
37,38 However, the application of
these cephalosporins may increase ESBL-producing E. colial Escherichia coli isolates associated with cow mastitis.
Table 5 Characterization of Escherichia coli isolates from cattle worldwide
Country Animal
condition
Source CTX-M type Other bla genes ESBL prevalence (%) Refs
China Healthy Rectal CTX-M14, CTX-M55 44
Switzerland Healthy Feces, Beef CTX-M1, 14,15, 117 blaTEM 13.7
14
Milk CTX-M1 blaTEM
Feces CTX-M9 group blaTEM 17.1
45
France Healthy Soil,
feces
CTX-M1 blaTEM-71
40
Diarrhea,
septicemia
Feces,
Blood
CTX-M1 group (65.7%),
CTX-M2 group (3.9%),
CTX-M9 group (27%)
blaTEM (3.4%) 100
46
Japan Diseased CTX-M2 blaTEM, blaCMY-2 2.8
43
Healthy Rectal CTX-M 12.5 47
Korea Healthy Feces CTX-M 0.2 48
Feces, Milk CTX-M14, CTX-M15,
CTX-M32
blaTEM-1
49
Ireland Diseased CTX-M2 blaCMY-2
36
United Kingdom Healthy Feces CTX-M1, 14, 15 39
Milk CTX-M15 blaTEM-1
50
Taiwan Clinical
mastitis
Milk CTX-M14, 15, 55 blaCMY, blaTEM,
blaSHV
11 This study
ESBL Z extended-spectrum b-lactamase.
Fluoroquinolone-resistant ESBL-E. coli from cow 899from animals, such as cattle, worldwide14,39e43 (Tables 4
and 5)14,36,39,40,43e50. The ESBL-producing isolates were
more prevalent in diseased cattle than healthy cattle and
were obtained from different sources. The blaCTX is the
most important ESBL-related gene for ESBL-producing E.
coli from cattle and its genotypes are associated with the
geographic area (Tables 3 and 5). The prevalent genotypes
of the blaCTX are blaCTX-M14 and blaCTX-M15 worldwide.
However, in this study, blaCTX-M55 in the isolates from Yunlin
and Tainan was the most prevalent genotype and has been
reported from cattle in China. The blaCTX-M55 isolates were
genetically identical from the same farm in Yunlin, implying
clonal dissemination of blaCTX-M55 E. coli in Yunlin.
In the present study, we determined blaCTM-M14, blaCTM-
M15, and blaCTM-M55 responsible for ESBL in E. coli. However,
blaCTM-M14 could not present simultaneously with blaCTX-M15
or blaCTM-M55 in the same isolate, indicating that blaCTM-M14
and blaCTX-M15 or blaCTM-M55 may exist mutually exclusively,
possibly on different incompatibility plasmids, and there-
fore, the transferability of blaCTM-M14 and blaCTX-M15 or
blaCTM-M55 associated elements need to be confirmed.
Additionally, some MDR ESBL-producing isolates carried
AmpA and AmpC bla genes simultaneously, such as blaCTX-M2
and blaCMY-2, in hospitalized animals (Table 5).
35 In the
present study, 28.1% isolates carried AmpA and AmpC genes
simultaneously (Table 3). Carbapenem-resistant E. coli can
occur in ESBL- and AmpC-producing E. coli isolates with
mutations in ompF and ompC genes,51,52 or be through
introduction of the chromosomal- and plasmid-encoded
carbapenamase, to become carbapenem-resistant.53
MDR fluoroquinolone-resistant ESBL isolates 31 and 58
with both AmpA and AmpC genes, differed in blaCTX-M ge-
notype and pulsotypes and were located in Chiayi and
Tainan, respectively. These results demonstrate different
origins of these two isolates. The presence of these isolatesin current cow farms and the mechanism of reduced sus-
ceptibility to carbapenem need to be further investigated.
To avoid the emergence of such resistant isolates and to
prevent the spreading of these isolates, the use of cepha-
losporins and fluoroquinolones should be limited in treating
cow infection isolates, and enhanced sanitation of milk
processing and transportation is needed.
In conclusion, genetically divergent E. coli isolates were
less resistant to traditional antimicrobials and not related
to human pathogens. Emergence of MDR fluoroquinolone-
resistant ESBL producers with reduced susceptibility to
carbapenem may threaten the public health.
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